EGFR and non-small cell lung carcinoma: Currently, NSCLC patients with specific genetic mutations, such as epidermal growth factor receptor (EGFR) E19 deletion/E21 L858R/E20 insertion mutation, Kirsten rat sarcoma (KRAS) G12C mutation, and others, have benefited from relevant targeted therapy [2–6].